Oltipraz chemoprevention trial in Qidong, People's Republic of China: Unaltered oxidative biomarkers

Free Radical Biology and Medicine

Volumn 41, Issue 6, 2006, Pages 1010-1014

  Glintborg, Bente ^a   Weimann, Allan ^a   Kensler, Thomas W ^b   Poulsen, Henrik E ^a  

^a Rigshospitalet   (Denmark)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aflatoxin; Chemoprevention; Free radicals; Oltipraz; Randomized clinical trial

Indexed keywords

8 HYDROXYGUANINE; AFLATOXIN; BIOLOGICAL MARKER; GUANINE; OLTIPRAZ; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER RISK; CARCINOGEN DNA INTERACTION; CHEMOPROPHYLAXIS; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DOUBLE BLIND PROCEDURE; DRUG DNA INTERACTION; DRUG EFFECT; FOLLOW UP; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; URINALYSIS;

ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHINA; DNA; GUANINE; HUMANS; LIVER NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLACEBOS; PYRAZINES;

EID: 33747339232     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.06.015     Document Type: Article

References (46)

1. Yang L., Parkin D.M., Ferlay J., Li L., and Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 243-250
2. Yu S.Z. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 10 (1995) 674-682
3. Jackson P.E., and Groopman J.D. Aflatoxin and liver cancer. Baillieres Best Pract. Res. Clin. Gastroenterol. 13 (1999) 545-555
4. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., and Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan childhood hepatoma study group. N. Engl. J. Med. 336 (1997) 1855-1859
5. Sudakin D.L. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J. Toxicol. Clin. Toxicol. 41 (2003) 195-204
6. De Flora, S.; Izzotti, A.; D'Agostini, F.; Balansky, R. M.; Noonan, D.; Albini, A. Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutat. Res. 480-481:9-22; 2001.
7. Helzlsouer K.J., and Kensler T.W. Cancer chemoprotection by oltipraz: experimental and clinical considerations. Prev. Med. 22 (1993) 783-795
8. Roebuck B.D., Curphey T.J., Li Y., Baumgartner K.J., Bodreddigari S., Yan J., Gange S.J., Kensler T.W., and Sutter T.R. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 24 (2003) 1919-1928
9. Egner P.A., Gange S.J., Dolan P.M., Groopman J.D., Munoz A., and Kensler T.W. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis 16 (1995) 1769-1773
10. Wang J.S., Shen X., He X., Zhu Y.R., Zhang B.C., Wang J.B., Qian G.S., Kuang S.Y., Zarba A., Egner P.A., Jacobson L.P., Munoz A., Helzlsouer K.J., Groopman J.D., and Kensler T.W. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl. Cancer Inst. 91 (1999) 347-354
11. Jacobson L.P., Zhang B.C., Zhu Y.R., Wang J.B., Wu Y., Zhang Q.N., Yu L.Y., Qian G.S., Kuang S.Y., Li Y.F., Fang X., Zarba A., Chen B., Enger C., Davidson N.E., Gorman M.B., Gordon G.B., Prochaska H.J., Egner P.A., Groopman J.D., Munoz A., Helzlsouer K.J., and Kensler T.W. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 257-265
12. Shen H.M., Ong C.N., Lee B.L., and Shi C.Y. Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation in rat hepatic DNA. Carcinogenesis 16 (1995) 419-422
13. Shen H.M., Shi C.Y., Shen Y., and Ong C.N. Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. Free Radic. Biol. Med. 21 (1996) 139-146
14. Evans M.D., Dizdaroglu M., and Cooke M.S. Oxidative DNA damage and disease: induction, repair and significance. Mutat. Res. 567 (2004) 1-61
15. Schwarz K.B., Kew M., Klein A., Abrams R.A., Sitzmann J., Jones L., Sharma S., Britton R.S., Di Bisceglie A.M., and Groopman J. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig. Dis. Sci. 46 (2001) 2173-2178
16. European Standards Committee on Oxidative DNA Damage. Comparison of different methods of measuring 8-oxoguanine as a marker of oxidative DNA damage. Free Radic. Res. 32 (2000) 333-341
17. Cooke M.S., Lunec J., and Evans M.D. Progress in the analysis of urinary oxidative DNA damage. Free Radic. Biol. Med. 33 (2002) 1601-1614
18. Cooke M.S., Evans M.D., and Lunec J. DNA repair: insights from urinary lesion analysis. Free Radic. Res. 36 (2002) 929-932
19. Gupta E., Olopade O.I., Ratain M.J., Mick R., Baker T.M., Berezin F.K., Benson III A.B., and Dolan M.E. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin. Cancer Res. 1 (1995) 1133-1138
20. Benson III A.B. Oltipraz: a laboratory and clinical review. J. Cell. Biochem. Suppl. 17F (1993) 278-291
21. Dimitrov N.V., Bennett J.L., McMillan J., Perloff M., Leece C.M., and Malone W. Clinical pharmacology studies of oltipraz-A potential chemopreventive agent. Invest. New Drugs 10 (1992) 289-298
22. Camoirano A., Bagnasco M., Bennicelli C., Cartiglia C., Wang J.B., Zhang B.C., Zhu Y.R., Qian G.S., Egner P.A., Jacobson L.P., Kensler T.W., and De Flora S. Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 775-783
23. Kensler T.W., He X., Otieno M., Egner P.A., Jacobson L.P., Chen B., Wang J.S., Zhu Y.R., Zhang B.C., Wang J.B., Wu Y., Zhang Q.N., Qian G.S., Kuang S.Y., Fang X., Li Y.F., Yu L.Y., Prochaska H.J., Davidson N.E., Gordon G.B., Gorman M.B., Zarba A., Enger C., Munoz A., and Helzlsouer K.J. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 127-134
24. Weimann A., Belling D., and Poulsen H.E. Quantification of 8-oxo-guanine and guanine as the nucleobase, nucleoside and deoxynucleoside forms in human urine by high-performance liquid chromatography-electrospray tandem mass spectrometry. Nucleic Acids Res. 30 (2002) E7
25. Weimann A., Belling D., and Poulsen H.E. Measurement of 8-oxo-2′-deoxyguanosine and 8-oxo-2′-deoxyadenosine in DNA and human urine by high performance liquid chromatography-electrospray tandem mass spectrometry. Free Radic. Biol. Med. 30 (2001) 757-764
26. Kensler T.W., Groopman J.D., Sutter T.R., Curphey T.J., and Roebuck B.D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12 (1999) 113-126
27. Chung F.L., Takahashi M., Schell P., Musser S.M., Kensler T.W., and Groopman J.D. Inhibition of aflatoxin Ml excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis 17 (1996) 1385-1388
28. Kensler T.W., Egner P.A., Dolan P.M., Groopman J.D., and Roebuck B.D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47 (1987) 4271-4277
29. Egner P.A., Gange S.J., Dolan P.M., Groopman J.D., Munoz A., and Kensler T.W. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis 16 (1995) 1769-1773
30. Walton M., Egner P., Scholl P.F., Walker J., Kensler T.W., and Groopman J.D. Liquid chromatography electrospray-mass spectrometry of urinary aflatoxin biomarkers: characterization and application to dosimetry and chemoprevention in rats. Chem. Res. Toxicol. 14 (2001) 919-926
31. Izzotti A., Balansky R.M., Dagostini F., Bennicelli C., Myers S.R., Grubbs C.J., Lubet R.A., Kelloff G.J., and De Flora S. Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. Cancer Res. 61 (2001) 2472-2479
32. Otieno M.A., Kensler T.W., and Guyton K.Z. Chemoprotective 3H-1,2-dithiole-3-thione induces antioxidant genes in vivo. Free Radic. Biol. Med. 28 (2000) 944-952
33. Primiano T., Kensler T.W., Kuppusamy P., Zweier J.L., and Sutter T.R. Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis 17 (1996) 2291-2296
34. Primiano T., Gastel J.A., Kensler T.W., and Sutter T.R. Isolation of cDNAs representing dithiolethione-responsive genes. Carcinogenesis 17 (1996) 2297-2303
35. Antras-Ferry J., Maheo K., Chevanne M., Dubos M.P., Morel F., Guillouzo A., Cillard P., and Cillard J. Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes. Carcinogenesis 18 (1997) 2113-2117
36. Prestera T., Talalay P., Alam J., Ahn Y.I., Lee P.J., and Choi A.M. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol. Med. 1 (1995) 827-837
37. Sharma R.A., and Farmer P.B. Biological relevance of adduct detection to the chemoprevention of cancer. Clin. Cancer Res. 10 (2004) 4901-4912
38. Gedik C.M., Boyle S.P., Wood S.G., Vaughan N.J., and Collins A.R. Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis 23 (2002) 1441-1446
39. Loft S., and Poulsen H.E. Measurement of oxidative damage to DNA nucleobases in vivo. In: Dizdaroglu K. (Ed). Advances in DNA damage and repair (1999), Kluwer Academic/Plenum, New York 267-281
40. Poulsen H.E., and Loft S. Interpretation of oxidative DNA modification: relation between tissue levels, excretion of urinary repair products. In: Halliwell B., and Aruoma O.I. (Eds). DNA and free radicals: techniques, mechanisms and applications (1998) 261-270
41. Jaruga P., and Dizdaroglu M. Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res. 24 (1996) 1389-1394
42. Poulsen H.E., Loft S., Jensen B.R., Sørensen M., Hoberg A.M., and Weimann A. HPLC-ECD, HPLC-MS/MS (urinary biomarkers). Crit. Rev. Oxid. Stress Aging (2004) 233-256
43. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 21 (2000) 361-370
44. Poulsen H.E., Loft S., and Vistisen K. Extreme exercise and oxidative DNA modification. J. Sports Sci. 14 (1996) 343-346
45. Prieme H., Loft S., Klarlund M., Gronbaek K., Tonnesen P., and Poulsen H.E. Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion. Carcinogenesis 19 (1998) 347-351
46. Loft S., Vistisen K., Ewertz M., Tjonneland A., Overvad K., and Poulsen H.E. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis 13 (1992) 2241-2247